Charles River(US:CRL)2025-05-07 11:35Financial Performance - Q1 2025 - Revenue decreased by 2.7% year-over-year to $984.2 million, with an organic revenue decline of 1.8%[24, 45] - GAAP EPS decreased by 61.5% year-over-year to $0.50, while non-GAAP EPS increased by 3.1% to $2.34[26, 45] - The company completed the repurchase of $350 million in common stock during 1Q25[47] - Free cash flow increased to $112.4 million compared to $50.7 million in 1Q24[48] Segment Performance - Q1 2025 - Discovery and Safety Assessment (DSA) revenue decreased by 2.1% to $592.6 million, with an organic decline of 1.4%[28] - Research Models and Services (RMS) revenue decreased by 3.5% to $213.1 million, with an organic decline of 2.5%[35] - Manufacturing Solutions revenue decreased by 3.6% to $178.5 million, with an organic decline of 2.2%[38] Updated 2025 Guidance - The company revised its 2025 revenue growth guidance to a decline of 5.5%-3.5% reported and a decline of 4.5%-2.5% organic[27, 51] - GAAP EPS estimate is $4.35-$4.85, and non-GAAP EPS estimate is $9.30-$9.80[27] - The company expects approximately flat organic revenue growth for RMS and approximately flat revenue for Manufacturing, while DSA organic revenue is expected to decline in the mid-single-digit range[52] NAMs (New Approach Methodologies) - CRL generated approximately $200 million in annual DSA revenue from NAMs, with the majority in discovery[13] - Chronic NHP studies longer than 3 months for mAbs represented approximately $50 million of the company's annual revenue[18] - Large Molecule accounted for ~25% of CRL safety assessment revenue mix in 2024, with mAbs accounting for ~10% and other biologics accounting for ~15%[20]